Abstract:Abstract Background / Objectives: A novel long-term animal model for human Graves’ disease (GD) was recently established in mice (Endocrinology 2015; 156: 1577-1589) using nine immunizations with recombinant adenovirus (Ad) expressing the extracellular A-subunit of the human thyrotropin receptor (TSHR) over 10 months. The aim of the present study is to detect and measure TSHR-Ab in the animal model of Ad-TSHR immunized mice. Methods: Female BALB/c mice received either 1010 plaque-forming units of adenovirus carrying the A-subunit of the TSHR gene or the green fluorescent protein (GFP) gene (injected into the femoral muscles). In addition, age-matched immunologically naïve mice were studied. Blood was withdrawn out of the left or right tail vein or intracardially (end of the study). The study protocol used three three-weekly immunizations (initiation), followed by a maintenance phase with further regular four-weekly boosts until the ninth immunization. Serum TSHR stimulating (TSAb) and -blocking (TBAb) Ab were measured with reporter bioassays. TSAb was reported as percentage of specimen-to-reference ratio (cut-off SRR% <140). Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine TSH alone (% inhibition <34). Results: A total of twenty-two BALB/c mice were studied (ten, eight, and four Ad-TSHR, control, and Ad-GFP-immunized mice, respectively). All twelve control- and Ad-GFP-immunized mice were negative for both thyrotropin-binding inhibitory immunoglobulins (TBII) as well as for TSAb and TBAb measured with the cell-based bioassays. In contrast, baseline TBII were highly positive in all Ad-TSHR-immunized mice (median 40 IU/L, 25%-75% percentiles 40-40 IU/L, normal cut-off 0.55 IU/L) All these mice also developed hyperthyroidism with elevated free T4 (fT4) levels (median 4.5 ng/dl, 25-75 percentile 4.1-6 ng/dl; normal range 0.9-1.8 ng/dl). All control (0.1, 0.1-0.1 IU/L) and Ad-GFP-immunized (0.2, 0.1-0.3 IU/L) mice were TBII negative and the corresponding fT4 levels were 2.2 ng/dl (2.1-2.4 ng/dl) and 2 ng/dl (1.9-2.1 ng/dl), respectively (p<0.001 for both TBII and fT4 versus Ad-TSHR mice). The serum positivity for TSAb and TBAb in a total of 28 consecutive samples obtained from ten Ad-TSHR mice was 12 (43%) and 21 (75%), respectively. Especially, serum samples of two (20%) Ad-TSHR mice were highly positive in the TSAb bioassay only with a SRR% value of 397 (329-465, p<0.001 vs. control mice). In comparison, sera of four Ad-TSHR mice (40%) were highly positive when measured with the TBAb bioassay only showing a % inhibition value of 69 (63-76). Furthermore, serum samples of four Ad-TSHR mice (40%) demonstrated dual TSAb/TBAb positivity. Conclusions: Functional TSHR-Ab are highly prevalent in Ad-TSHR immunized mice, thus confirming the successful establishment of a novel, long-term animal model for GD.

Peptidomic profiling of endogenous peptides in the spleens of mouse models of Graves' disease

The Significance Of Immune-Related Molecule Expression Profiles In An Animal Model Of Graves' Disease

The Immune Responses in Graves' Disease Mouse Model As Investigated Through Synthetic Linear Peptides

Impairment of Regulatory Capacity of Cd4(+)Cd25(+) Regulatory T Cells Mediated by Dendritic Cell Polarization and Hyperthyroidism in Graves' Disease

Expression of IFNα-inducible Genes and Modulation of HLA-DR and Thyroid Stimulating Hormone Receptors in Graves’ Disease

Identification of two potential biomarkers of Graves' Disease by bioinformatics analyses based on Gene Expression Omnibus datasets with immune cells infiltration.

SAT-557 Functional Thyrotropin Receptor Antibodies Confirm a Novel Graves' Disease Animal Model

Studies on the development of a mouse model of Graves' disease

Mouse model of Graves' orbitopathy induced by the immunization with TSHR A and IGF-1R α subunit gene

Insight Into Mouse Models of Hyperthyroidism

Identification of Two Potential Immune-Related Biomarkers of Graves’ Disease Based on Integrated Bioinformatics Analyses

Investigating the mechanism and efficacy material basis of Xiehuo Xiaoying decoction for treating Graves' disease via thyroid cell apoptosis based on proteomics and molecular docking techniques

A Global Regulatory Network for Dysregulated Gene Expression and Abnormal Metabolic Signaling in Immune Cells in the Microenvironment of Graves’ Disease and Hashimoto’s Thyroiditis

Microarray profile of B cells from Graves' disease patients reveals biomarkers of proliferation

A Promising Mouse Model of Graves' Orbitopathy Induced by Adenovirus Expressing Thyrotropin Receptor A Subunit

The Influence of Dihydrotestosterone on the Development of Graves' Disease in Female Balb/C Mice

T-cell exhaustion-related genes in Graves' disease: a comprehensive genome mapping analysis

Constitutive Changes in Circulating Follicular Helper T Cells and Their Subsets in Patients with Graves’ Disease

Elevated Expression and Activation of GPR15 in Immune Cells in Graves' Disease

Microarray Profiling and Functional Analysis of Differentially Expressed Plasma Exosomal Circular RNAs in Graves' Disease.

Dihydrotestosterone Regulates Oxidative Stress and Immunosuppressive Cytokines in a Female BALB/c Mouse Model of Graves' Disease.